Evidence map›Paper›PMID 30542479›Full record

ArticleExperimental and therapeutic medicine2018

Effects of Hochuekkito combined with pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.

Hironobu Hamada, Kiyokazu Sekikawa, Isao Murakami, Kouichi Aimoto, Kazuyoshi Kagawa, Tatsuya Sumigawa, Ken Okusaki, Takefumi Dodo, Yoshikazu Awaya, Masatoshi Watanabe and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Hironobu HamadaDepartment of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
Kiyokazu SekikawaDepartment of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
Isao MurakamiDepartment of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.
Kouichi AimotoDepartment of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.
Kazuyoshi KagawaDepartment of Respiratory Medicine, Hiroshima City Medical Association-Administered Hiroshima City Aki Hospital, Hiroshima, Hiroshima 736-0088, Japan.
Tatsuya SumigawaDepartment of Respiratory Medicine, Hiroshima City Medical Association-Administered Hiroshima City Aki Hospital, Hiroshima, Hiroshima 736-0088, Japan.
Ken OkusakiDepartment of Internal Medicine, Mihara Medical Associations Hospital, Mihara, Hiroshima 723-0051, Japan.
Takefumi DodoDepartment of Internal Medicine, Mihara Medical Associations Hospital, Mihara, Hiroshima 723-0051, Japan.
Yoshikazu AwayaDepartment of Respiratory Medicine, Miyoshi Central Hospital, Miyoshi, Hiroshima 728-8502, Japan.
Masatoshi WatanabeDepartment of Respiratory Medicine, Miyoshi Central Hospital, Miyoshi, Hiroshima 728-8502, Japan.
Keiichi KondoDepartment of Respiratory Medicine, Tadanoumi Hospital, Takehara, Hiroshima 729-2316, Japan.
Takashi OgawaDepartment of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.
Hikaru YamamotoDepartment of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
Noboru HattoriDepartment of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
Hiroshima University · JPHigashihiroshima Medical Center · JPHiroshima City Asa Citizens Hospital · JPAzumi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) has significant systemic effects, such as weight loss, which affects exercise capacity, health-related quality of life (HRQOL) and survival. The traditional herbal medicine, Hochuekkito (TJ-41), improves the nutritional status and decreases systemic inflammation in patients with COPD. However, to date, the additive effect of TJ-41 on pulmonary rehabilitation (PR) in patients with COPD has not been researched comprehensively. The purpose of the present study was to investigate the efficacy and safety of adding TJ-41 to PR for patients with COPD. Thirty-three malnourished patients with COPD were randomly assigned to receive low-intensity exercise with (TJ-41 group) or without (control group) TJ-41 treatment for 12 weeks. The primary outcome was the change in the 6-min walk distance (6MWD). Secondary outcomes included changes in the body composition, peripheral muscle strength, modified Medical Research Council dyspnea score, visual analog scale (VAS) score for dyspnea, VAS score for fatigue and COPD assessment test (CAT) score. After the 12-week treatment, body weight and percent ideal body weight were significantly increased in the TJ-41 group (P<0.05), but not in the control group. After the 12-week treatment, the modified Medical Research Council dyspnea score, VAS score for dyspnea, VAS score for fatigue and total CAT score decreased significantly in the TJ-41 group (all P<0.05), but not in the control group. There were no significant differences in the 6MWD and peripheral muscle strength between baseline and after 12 weeks of treatment in either group. No adverse effects were noted with the use of TJ-41. It was concluded that the addition of TJ-41 to PR may benefit malnourished patients with COPD with respect to dyspnea and HRQOL.

Indexed as

chronic obstructive pulmonary diseasedyspneahealth-related quality of lifeherbal medicineHochuekkito

Identifiers

PMID30542479
PMCPMC6257386
OpenAlexW2897935102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.